kat6 inhibitor men2312
Generic: KAT6 Inhibitor MEN2312
kat6 inhibitor men2312: 1 clinical trial tracked.
kat6 inhibitor men2312 evidence translation
What we can confirm
1 tracked trial
No verified listed developer
What it means
AI will separate confirmed drug evidence from unknown company context.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
What is verified about kat6 inhibitor men2312, and what remains unknown?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 1 study sponsors
Related indications
Study sponsors
Clinical Trials (1)
A Phase 1, First-in-Human Study of MEN2312, a KAT6 Inhibitor, as Monotherapy and in Combination in Participants With Advanced Breast Cancer
Primary endpoint: Number of Participants Experiencing Dose-limiting Toxicity When Administered MEN2312
InterventionalRandomizedopen240 targetStarted 2024-10Completion 2026-1042 sites · Spain, United StatesStemline Therapeutics, Inc.